Sign in

ICPT on NASDAQ

Intercept Pharmaceuticals

Logo: Intercept Pharmaceuticals, Public domain, via Wikimedia Commons5

Pharmaceutical company

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.3 Its shares trade on NASDAQ under the symbol ICPT.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

2002Founded1

Compare with Aurinia Pharmaceuticals Inc., Xeris Biopharma Holdings, Inc. or RIGEL PHARMACEUTICALS INC, or pick any stock.

  • TickerICPT on NASDAQ1
  • Industrybiotechnology, pharmaceutical industry1
  • HeadquartersNew York City1
  • Websitewww.interceptpharma.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address305 Madison Avenue, Morristown, Nj 079606
  • Filer categoryAccelerated filer6
  • LEI254900JMB8TX5P688V244
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressc/o The Corporation Trust Company, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 35652134

See how the biggest companies compare on our leaderboards

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-23.9%Operating margin8
77.6%Net margin8
9.6%Revenue growth, 20228
238.3%Return on equity8
2.40×Debt to equity8
-$27.3MFree cash flow8

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue0¢$984.0K
  • Research and development30¢$176.6M
  • Selling, general and admin30¢$176.3M
  • Interest4¢$21.4M
  • Profit37¢$221.8M

Out of $285.7M in revenue.8

Financial statements

Revenue91011128$285.7M in 2022+1045% since 2016
0$100.0M$200.0M$300.0M2016: $25.0M$25.0M20162017: $131.0M$131.0M2017+425%2018: $179.8M$179.8M2018+37%2019: $252.0M$252.0M2019+40%2020: $234.0M$234.0M2020−7%2021: $260.8M$260.8M2021+11%2022: $285.7M$285.7M2022+10%
Operating income91011128-$68.2M in 2022−83% since 2016
-$600.0M-$400.0M-$200.0M02016: -$402.5M-$402.5M20162017: -$335.6M-$335.6M2017−17%2018: -$285.5M-$285.5M2018−15%2019: -$312.4M-$312.4M2019+9%2020: -$229.7M-$229.7M2020−26%2021: -$100.4M-$100.4M2021−56%2022: -$68.2M-$68.2M2022−32%
Net income91011128$221.8M in 2022
-$600.0M-$400.0M-$200.0M0$200.0M$400.0M2016: -$412.8M-$412.8M20162017: -$360.4M-$360.4M2017−13%2018: -$309.2M-$309.2M2018−14%2019: -$344.7M-$344.7M2019+11%2020: -$274.9M-$274.9M2020−20%2021: -$91.4M-$91.4M2021−67%2022: $221.8M$221.8M2022
Fiscal year2016201720182019202020212022
Revenue$25.0M9$131.0M10$179.8M11$252.0M12$234.0M8$260.8M8$285.7M8
Cost of revenue$1.4M10$2.5M11$4.2M12$2.4M8$1.2M8$984.0K8
Research and development$153.9M9$191.5M10$207.3M11$242.8M12$189.0M8$182.7M8$176.6M8
Selling, general and admin$273.6M9$273.7M10$255.5M11$317.4M12$260.5M8$177.5M8$176.3M8
Operating expenses$361.2M8$353.9M8
Operating income-$402.5M9-$335.6M10-$285.5M11-$312.4M12-$229.7M8-$100.4M8-$68.2M8
Interest$14.2M9$29.3M10$30.5M11$41.1M12$48.1M8$54.4M8$21.4M8
Income before tax-$136.4M8-$174.9M8
Net income-$412.8M9-$360.4M10-$309.2M11-$344.7M12-$274.9M8-$91.4M8$221.8M8
Earnings per share-$10.8912-$8.348-$2.878$6.568
Earnings per share (diluted)-$10.8912-$8.348-$2.878$6.568
Shares (weighted, basic)31.9M shares833.8M shares8
Shares (weighted, diluted)31.9M shares833.8M shares8

Compare Intercept Pharmaceuticals with another company

Corporate structure

Intercept Pharmaceuticals sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Intercept Pharmaceuticals

  • VANGUARD GROUP INC Filed SC 13G/A on Intercept Pharmaceuticals, latest Oct 10, 2023 (4 filings since Feb 10, 2022)
  • BlackRock Filed SC 13G/A on Intercept Pharmaceuticals, latest Jul 7, 2023 (3 filings since Feb 3, 2022)
  • Point72 Asset Management, L.P. Filed SC 13G/A on Intercept Pharmaceuticals, latest Feb 14, 2023 (2 filings since Oct 12, 2022)
  • State Street Corporation Filed SC 13G/A on Intercept Pharmaceuticals, latest Feb 2, 2023 (3 filings since Dec 10, 2021)
  • MILLENNIUM MANAGEMENT LLC Filed SC 13G/A on Intercept Pharmaceuticals, latest Jan 13, 2023 (2 filings since Aug 18, 2022)
  • FMR LLC Filed SC 13G/A on Intercept Pharmaceuticals, latest Oct 11, 2022 (2 filings since Feb 9, 2022)
  • Genextra S.p.A. Filed SC 13G/A on Intercept Pharmaceuticals, latest Sep 2, 2022
  • FIRST TRUST PORTFOLIOS LP Filed SC 13G/A on Intercept Pharmaceuticals, latest Feb 2, 2022
  • Intercept Pharmaceuticals Morristown, New Jersey, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Intercept Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.8M8 Dec 31, 2022$21.4M8 Dec 31, 2021−77.6%
Accumulated depreciation$3.8M8 Dec 31, 2022$18.1M8 Dec 31, 2021−79.0%
Property and equipment, net$987.0K8 Dec 31, 2022$3.3M8 Dec 31, 2021−69.9%
Operating-lease assets (leased space)$6.1M12 Dec 31, 2021$12.3M12 Dec 31, 2020−50.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$50.5M8 Dec 31, 2022$84.7M8 Dec 31, 2021−40.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$6.5M8 Dec 31, 2022$7.9M8 Dec 31, 2021−18.0%
Work in process$6.2M8 Dec 31, 2022$7.8M8 Dec 31, 2021−20.1%
Finished goods$232.0K8 Dec 31, 2022$82.0K8 Dec 31, 2021+182.9%

The story

Intercept traded on the NASDAQ exchange under the ticker symbol ICPT. The initial public offering of the stock on October 16, 2012 was at $15. A follow-on public offering at $33 took place on June 24, 2013.

On January 9, 2014, the stock skyrocketed from $72.39 to $275.49, or about 280%, after a planned interim analysis by the independent data safety monitoring board showed that Obeticholic acid met the main goal (improvement of liver histology) at the mid-stage in the FLINT trial in NASH, sponsored by NIDDK. The stock continued to climb to $497 over the next few days before falling back to around $317 on March 29, 2014, giving a market capitalization of around $6.2 billion.

In March 2014, the company released the results of the POISE study of Obeticholic acid in PBC, which showed the drug met the trial's primary endpoint of a reduction in serum alkaline phosphatase, a biomarker for the disease. These results were presented at an international liver meeting in April 2014.

As of 31 December 2014, the company has 136 employees.

In 2023, Intercept Pharmaceuticals was acquired by Italian Alfasigma S.p.A for $19.00 per share in cash (approximately $800 million).

From Wikipedia’s article on Intercept Pharmaceuticals, shared under CC BY-SA 4.0.7

Leadership

Who has led Intercept Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mark Pruzanski2012–2020
  2. Jerome Benedict Durso2021–2023

President

  1. Mark Pruzanski2012–2020
  2. Lisa Bright2016–2020
  3. Richard J. Kim2018–2021
  4. Jerome Benedict Durso2021–2023
  5. M. Michelle Berrey2021–2023

Chief financial officer

  1. Barbara Gayle Duncan2012–2016
  2. Sandip Kapadia2016–2021
  3. Andrew Saik2021–2023

Chief operating officer

  1. Jerome Benedict Durso2017–2020
20052010201520202025
Board members and other officers (33)

Products and brands

The company's lead product is Ocaliva (obeticholic acid, OCA), also known as 6-ethyl-chenodeoxycholic acid or INT-747. OCA is a potent first-in-class farnesoid X receptor (FXR) agonist. In 2016, the U.S. Food and Drug Administration (FDA) approved Ocaliva for use in primary biliary cholangitis.

In June 2024, the European Medicines Agency (EMA) recommended revoking the conditional marketing authorization for Ocaliva. The decision followed a review by the Committee for Medicinal Products for Human Use (CHMP), which concluded that the benefits of Ocaliva no longer outweigh its risks. The European Commission officially revoked Ocaliva's marketing authorization on August 30, 2024.

In November 2024, the U.S. Food and Drug Administration (FDA) declined to grant full approval for Ocaliva as a treatment for primary biliary cholangitis (PBC), a rare autoimmune liver disease. This decision followed a September 2024 advisory committee meeting where 13 out of 14 panel members concluded that Intercept's data did not adequately demonstrate Ocaliva's clinical benefit. Consequently, the FDA issued a complete response letter, indicating that the supplemental new drug application could not be approved in its current form. Despite this setback, Ocaliva remains available in the U.S. under the accelerated approval granted in 2016, which requires ongoing post-marketing studies to confirm its clinical benefits. The FDA is continuing to review data from these studies, including trial 747-302 (NCT02308111), and has noted concerns about serious liver injury in some patients without severe scarring.

Other products in the development pipeline include INT-767, a dual FXR/TGR5 agonist, and INT-777, a TGR5 agonist.

Read the full text

On June 29, 2020, the company released a statement announcing that FDA had rejected its lead product obeticholic acid, OCA, because FDA officials had determined that "the predicted benefit of the drug does not sufficiently outweigh the predicted risks".

From Wikipedia’s article on Intercept Pharmaceuticals, shared under CC BY-SA 4.0.7

Former names

  • INTERCEPT PHARMACEUTICALS INCNov 12, 2003 to Apr 12, 20186

Timeline

  1. Nov 8, 20238-K Entered a material agreement; Completed an acquisition or sale; Debt or obligation accelerated57
  2. Sep 26, 20238-K Entered a material agreement; Other events58
  3. Aug 2, 20238-K Results of operations59
  4. Jun 23, 20238-K Regulation FD disclosure60
  5. Jun 23, 20238-K Exit or restructuring costs; Regulation FD disclosure61
  6. May 25, 20238-K Shareholder vote62
  7. May 22, 20238-K Regulation FD disclosure63
  8. May 18, 20238-K Entered a material agreement; Other events64
  9. Apr 27, 20238-K Results of operations65
  10. Mar 24, 20238-K Entered a material agreement; Other events66
  11. Mar 2, 20238-K Results of operations67
  12. Feb 27, 20238-K Other events68
  13. Jan 5, 2021New chief executive Jerome Benedict Durso becomes CEO17
  14. Oct 10, 2012New chief executive Mark Pruzanski becomes CEO18
  15. 2002Founded Founded1

Calendar

When it reported results

  1. Aug 2, 2023Reported quarterly or annual results59
  2. Apr 27, 2023Reported quarterly or annual results65
  3. Mar 2, 2023Reported quarterly or annual results67
  4. Nov 1, 2022Reported quarterly or annual results69
  5. Aug 3, 2022Reported quarterly or annual results70
  6. May 6, 2022Reported quarterly or annual results71
  7. Mar 2, 2022Reported quarterly or annual results72
  8. Nov 3, 2021Reported quarterly or annual results73

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

225 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 53 major events, 104 insider forms, 18 large holders, 41 other. The latest 20:

  1. Nov 20, 202315-12G EDGAR
  2. Nov 14, 2023EFFECT EDGAR
  3. Nov 14, 2023EFFECT EDGAR
  4. Nov 14, 2023EFFECT EDGAR
  5. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  6. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  7. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  8. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  9. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  10. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  11. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  12. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  13. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  14. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  15. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  16. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  17. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  18. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  19. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR
  20. Nov 13, 20234 OWNERSHIP DOCUMENT EDGAR

The 225 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Intercept Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARINTERCEPT PHARMACEUTICALS, INC.2
  • CIK0001270073
  • Employer ID (EIN)22-38684592
  • Filer statusAccelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address305 Madison Avenue, Morristown, NJ 079602
  • Phone646-747-10002
  • Shares outstanding41,825,966 as of Nov 2, 202315
  • Public float$335.2M as of Jun 30, 20228
  • On EDGAR sinceNov 12, 20032
  • Filings1,265 in all: 4 (787), 8-K (175), SC 13G/A (49), 3 (39), 10-Q (34), 424B5 (15), SC 13G (14), CT ORDER (12)2
    All 49 form types

    10-K (11), DEF 14A (11), S-8 (9), S-8 POS (9), CORRESP (8), UPLOAD (7), EFFECT (6), SC 13D/A (5), 5 (4), PRE 14A (4), S-1/A (4), SC 14D9/A (4), SC TO-C (4), SC TO-I/A (4), SC TO-T/A (4), SC14D9C (4), 10-K/A (3), 8-K/A (3), FWP (3), POS AM (3), S-1 (3), S-3ASR (3), 305B2 (2), 424B4 (2), DEFA14A (2), REGDEX (2), SC 13D (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 4/A (1), 424B1 (1), 8-A12B (1), ARS (1), CERTNAS (1), D (1), D/A (1), S-1MEF (1), SC 14D9 (1), SC TO-I (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 2, 2023
    Quarterly report (10-Q) Nov 6, 2023
    Proxy statement (DEF 14A) May 1, 2023
    Latest 8-K (8-K) Nov 8, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
    SEC EDGAROther events
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81